MX2021001039A - Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas. - Google Patents

Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas.

Info

Publication number
MX2021001039A
MX2021001039A MX2021001039A MX2021001039A MX2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A MX 2021001039 A MX2021001039 A MX 2021001039A
Authority
MX
Mexico
Prior art keywords
hematological malignancy
patients
stem cell
hematopoietic stem
cell transplantation
Prior art date
Application number
MX2021001039A
Other languages
English (en)
Inventor
Christoph Bucher
Peter Gergely
Claudia Corrado
Julie Jones
Original Assignee
Priothera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Ltd filed Critical Priothera Ltd
Publication of MX2021001039A publication Critical patent/MX2021001039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una preparación farmacéutica que inhibe la reaparición de malignidades hematológicas y/o mejora las tasas de supervivencia, en pacientes quienes han pasado por trasplante de células madre hematopoyéticas para el tratamiento de malignidades hematológicas, la cual contiene 2-amino-2-[4-(3-benciloxifeniltio) -2-clorofenil]etil-propano-1,3-diol o una sal farmacéuticamente aceptable del mismo como un ingrediente activo.
MX2021001039A 2018-07-27 2019-07-26 Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas. MX2021001039A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018141411 2018-07-27
JP2019036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Publications (1)

Publication Number Publication Date
MX2021001039A true MX2021001039A (es) 2021-04-12

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001039A MX2021001039A (es) 2018-07-27 2019-07-26 Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas.

Country Status (12)

Country Link
US (1) US20210283073A1 (es)
EP (1) EP3831370A4 (es)
JP (1) JP7389486B2 (es)
KR (1) KR20210040954A (es)
CN (1) CN112512516A (es)
AU (1) AU2019311609A1 (es)
BR (1) BR112021001376A2 (es)
CA (1) CA3106608A1 (es)
IL (1) IL280451A (es)
MX (1) MX2021001039A (es)
TW (1) TW202011948A (es)
WO (1) WO2020022507A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023008907A (es) 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
CN101277687B (zh) 2005-10-07 2012-07-18 杏林制药株式会社 以2-氨基-1,3-丙二醇衍生物作为有效成分的肝脏疾病治疗剂及肝脏疾病治疗方法
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2009094157A1 (en) * 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
US10407727B2 (en) * 2013-01-30 2019-09-10 Memorial Sloan Kettering Cancer Center Donor KIR3DL1 and HLA-B subtypes and leukemia control in HLA-compatible allogenic hematopoietic stem cell transplantation
EA030783B1 (ru) * 2013-02-20 2018-09-28 Керин Фармасьютикал Ко., Лтд. Способ лечения и/или предупреждения реакции "трансплантат против хозяина" у пациента, подвергаемого трансплантации гемопоэтических стволовых клеток
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof
CN108778310B (zh) 2016-03-08 2022-08-19 普莱欧塞拉有限公司 造血干细胞移植患者的处理

Also Published As

Publication number Publication date
JP7389486B2 (ja) 2023-11-30
EP3831370A4 (en) 2022-04-27
US20210283073A1 (en) 2021-09-16
BR112021001376A2 (pt) 2021-04-20
IL280451A (en) 2021-03-25
WO2020022507A1 (ja) 2020-01-30
JPWO2020022507A1 (ja) 2021-08-05
KR20210040954A (ko) 2021-04-14
CN112512516A (zh) 2021-03-16
TW202011948A (zh) 2020-04-01
EP3831370A1 (en) 2021-06-09
AU2019311609A1 (en) 2021-02-04
CA3106608A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2021001039A (es) Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
BR112021011289A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015006176A8 (pt) método de tratamento de câncer em um indivíduo com necessidade de tratamento
MX2019014410A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
PH12020500276A1 (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
NI201500100A (es) Mã‰todos de tratamiento de la deficiencia de hierro con pirofosfato fã‰rrico soluble
NZ711500A (en) Engineering a control drug release profile via liposome compositions in both aqueous and non-aqueous compartments
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2018006409A (es) Articulo que contiene celulosa, biotecnologicamente producida, para uso dermatologico.
BR112017026140A2 (pt) método para inibir o crescimento ou a proliferação de células cancerígenas, método para induzir apoptose em célula cancerígena, método para tratar câncer, composição e seu uso
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2018074862A3 (ko) Tha를 유효성분으로 포함하는 유방암 치료용 약학적 조성물
IL250852B (en) Periodontal preparation
MX2020002336A (es) Composicion lipolitica que contiene derivados de fosfocolina.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
BR112019022459A2 (pt) Agente terapêutico para câncer no sangue
EA202190132A1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток